IN2012DN02580A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02580A
IN2012DN02580A IN2580DEN2012A IN2012DN02580A IN 2012DN02580 A IN2012DN02580 A IN 2012DN02580A IN 2580DEN2012 A IN2580DEN2012 A IN 2580DEN2012A IN 2012DN02580 A IN2012DN02580 A IN 2012DN02580A
Authority
IN
India
Prior art keywords
mglur4
allosteric
compounds useful
glutamate receptor
receptor subtype
Prior art date
Application number
Inventor
P Jeffrey Conn
Craig W Lindsley
Corey R Hopkins
Charles David Weaver
Colleen M Niswender
Darren W Engers
Yiu-Yin Cheung
Patrick R Gentry
James M Salovich
Rocco D Gogliotti
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of IN2012DN02580A publication Critical patent/IN2012DN02580A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compounds useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4) and use thereof.
IN2580DEN2012 2009-09-04 2010-09-07 IN2012DN02580A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24003109P 2009-09-04 2009-09-04
PCT/US2010/048030 WO2011029104A1 (en) 2009-09-04 2010-09-07 Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

Publications (1)

Publication Number Publication Date
IN2012DN02580A true IN2012DN02580A (en) 2015-08-28

Family

ID=43649686

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2580DEN2012 IN2012DN02580A (en) 2009-09-04 2010-09-07

Country Status (12)

Country Link
US (1) US8779157B2 (en)
EP (1) EP2473055A4 (en)
JP (1) JP2013503909A (en)
CN (1) CN102740699A (en)
AU (1) AU2010289281A1 (en)
BR (1) BR112012004919A2 (en)
CA (1) CA2773038A1 (en)
IL (1) IL218426A0 (en)
IN (1) IN2012DN02580A (en)
RU (1) RU2012114770A (en)
SG (1) SG178999A1 (en)
WO (1) WO2011029104A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2751176A1 (en) 2009-01-28 2010-08-05 Vanderbilt University Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8759377B2 (en) 2009-11-23 2014-06-24 Vanderbilt University Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
HUE034849T2 (en) * 2013-09-25 2018-03-28 Hoffmann La Roche Ethynyl derivatives
EP2853532B1 (en) 2013-09-28 2020-12-09 Instytut Farmakologii Polskiej Akademii Nauk 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
TWI649310B (en) * 2014-01-10 2019-02-01 赫孚孟拉羅股份公司 Acetylene derivative
CR20160384A (en) * 2014-02-25 2016-11-07 Hoffmann La Roche ETHYLIN DERIVATIVES
US10221172B2 (en) 2015-01-13 2019-03-05 Vanderbilt University Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2016123629A1 (en) 2015-01-30 2016-08-04 Vanderbilt University Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US10227343B2 (en) 2015-01-30 2019-03-12 Vanderbilt University Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
CN107207481B (en) * 2015-03-19 2020-03-03 豪夫迈·罗氏有限公司 3- (4-ethynylphenyl) hexahydropyrimidine-2, 4-dione derivatives as modulators of MGLUR4
US9987242B2 (en) 2015-05-05 2018-06-05 Northwestern University Treatment of Levodopa-induced Dyskinesias
PE20180356A1 (en) 2015-07-15 2018-02-21 Hoffmann La Roche ETHINYL DERIVATIVES AS MODULATORS OF THE METABOTROPIC GLUTAMATE RECEPTOR
CN109476671B (en) 2016-07-18 2021-09-24 豪夫迈·罗氏有限公司 Ethynyl derivatives
US10294222B2 (en) 2016-09-01 2019-05-21 Vanderbilt University Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US10710997B2 (en) 2016-09-01 2020-07-14 Vanderbilt University Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US11242342B2 (en) 2016-11-08 2022-02-08 Vanderbilt University Isoquinoline amine compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2018089546A1 (en) 2016-11-08 2018-05-17 Vanderbilt University Isoquinoline ether compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2019006157A1 (en) 2017-06-28 2019-01-03 Vanderbilt University Pyridine quinoline compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
UA128084C2 (en) 2017-08-16 2024-04-03 Вандербілт Юніверсіті Indazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
AU2019309448A1 (en) 2018-07-26 2021-01-14 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mGluR4

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK529378A (en) 1978-01-09 1979-07-10 Shell Int Research anilide
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2725206B1 (en) 1994-09-29 1996-12-06 Roussel Uclaf NOVEL HETEROCYCLE SUBSTITUTED IMIDAZOLIDINES, THEIR PROCESS AND PREPARATION INTERMEDIATES, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
USRE38132E1 (en) 1997-03-03 2003-06-03 Boehringer Ingelheim Pharmaceuticals, Inc. Phenylpyrrolidines, phenylimidazolidines,3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease
US6355664B1 (en) 1997-03-03 2002-03-12 Boehringer Ingelheim Pharmaceuticals, Inc. Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease
FR2764889B1 (en) 1997-06-20 2000-09-01 Sod Conseils Rech Applic NOVEL 2- (IMINOMETHYL) AMINO-PHENYL DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6809088B2 (en) 1997-03-24 2004-10-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
US6335445B1 (en) 1997-03-24 2002-01-01 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
WO2000077519A1 (en) 1999-06-15 2000-12-21 Aventis Pharmaceuticals Products Inc. Solid phase synthesis of n,n-disubstituted diazacycloalkylcarboxy derivatives
WO2001007052A1 (en) 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
US6353013B1 (en) 1999-07-21 2002-03-05 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
WO2001046195A1 (en) 1999-12-21 2001-06-28 Gpi Nil Holdings, Inc. Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
EP1397137B1 (en) 2001-05-25 2009-10-14 Bristol-Myers Squibb Company Hydantion derivatives as inhibitors of matrix metalloproteinases
CA2462112A1 (en) 2001-10-01 2003-04-10 Bristol-Myers Squibb Company Spiro-hydantoin compounds useful as anti-inflammatory agents
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
AU2003259307A1 (en) 2002-07-31 2004-02-16 Euro-Celtique S.A. Aryl substituted hydantoin compounds and their use as sodium channel blockers
US7053112B2 (en) 2002-09-24 2006-05-30 Schering Aktiengesellschaft Imidazolidinedione analogs useful as anticoagulants and antithrombotics
AU2004255414A1 (en) 2003-07-11 2005-01-20 Boehringer Ingelheim Vetmedica Gmbh Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor
JP2007506741A (en) * 2003-09-23 2007-03-22 メルク　エンド　カムパニー　インコーポレーテッド Pyrazole modulators of metabotropic glutamate receptors
TWI345568B (en) * 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
JP4810426B2 (en) * 2004-07-01 2011-11-09 第一三共株式会社 Thienopyrazole derivative having PDE7 inhibitory action
UY29896A1 (en) * 2005-11-04 2007-06-29 Astrazeneca Ab NEW CHROMAN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
EP2061767B1 (en) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
GB0713686D0 (en) 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
PE20090967A1 (en) 2007-10-16 2009-08-10 Novartis Ag DERIVATIVES OF IMIDAZOLIDINE 2,4-DIONA AS MODULATORS OF THE NPY Y2 RECEPTOR

Also Published As

Publication number Publication date
BR112012004919A2 (en) 2019-09-24
WO2011029104A1 (en) 2011-03-10
US20120245153A1 (en) 2012-09-27
EP2473055A4 (en) 2013-02-13
CA2773038A1 (en) 2011-03-10
EP2473055A1 (en) 2012-07-11
US8779157B2 (en) 2014-07-15
AU2010289281A1 (en) 2012-04-12
CN102740699A (en) 2012-10-17
SG178999A1 (en) 2012-04-27
IL218426A0 (en) 2012-04-30
RU2012114770A (en) 2013-10-10
JP2013503909A (en) 2013-02-04

Similar Documents

Publication Publication Date Title
IN2012DN02580A (en)
MX2012013031A (en) Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction.
MY181898A (en) Heterocyclic compounds and uses thereof
MX2012007507A (en) Heteroaryl compounds and uses thereof.
MX2010008714A (en) Amide derivatives as positive allosteric modulators and methods of use thereof.
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
GT201300164A (en) BICYCLE DERIVATIVES (3.2.1.) OCTILAMIDA AND ITS USES
MY160490A (en) Arylethynyl derivatives
MY153975A (en) Pyridine derivatives as s1p1/edg1 receptor modulators
EP2569330A4 (en) Chlorotoxin variants, conjugates, and methods for their use
TN2012000195A1 (en) Solid dispersion of rifaximin
MY161170A (en) Pyrimidine cyclohexyl glucocorticoid receptor modulators
MX2009009415A (en) Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor.
MX2009007284A (en) Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts.
IN2012DN02876A (en)
HK1167404A1 (en) Benzothiadiazepine derivatives used as ampa and nmda receptor modulators ampa nmda
WO2009089234A3 (en) Substituted dibenzhydrylpiperazines
HK1142608A1 (en) 5-pyridinone substituted indazoles and pharmaceutical compositions thereof 5-
EP2477631A4 (en) Substituted phenylamine carboxamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
EP2670731A4 (en) Positive allosteric modulators of the alpha 7 nicotinic acetylcholine receptor and uses thereof.
MY158253A (en) Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor
EP2576575A4 (en) Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof
WO2009132119A3 (en) Substituted oxazolidinones
IN2012DN01379A (en)
AU2009235634A8 (en) Substituted sulfonamide derivatives